Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Precision BioSciences (DTIL)
NASDAQ:DTIL
Precision BioSciences (DTIL) Stock Price & Analysis
524 Followers
DTIL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.80 - $3.44
Previous Close$0.85
Volume736.39K
Average Volume (3M)609.74K
Market Cap
$94.60M
Enterprise Value-$67.94M
Total Cash (Recent Filing)$189.58M
Total Debt (Recent Filing)$27.04M
Price to Earnings (P/E)-0.6
Beta1.63
Next Earnings
May 10, 2023EPS Estimate
-$0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.39
Shares Outstanding110,958,955
10 Day Avg. Volume647,338
30 Day Avg. Volume609,741
Standard Deviation0.35
R-Squared0.05
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.60
Price to Sales (P/S)9.34
Price to Cash Flow (P/CF)521.80
P/FCF Ratio-5.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-2.71
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.67
Forecast
1Y Price Target
$10.50Price Target Upside1135.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Precision BioSciences News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DTIL FAQ
What was Precision BioSciences’s price range in the past 12 months?
Precision BioSciences lowest stock price was $0.80 and its highest was $3.44 in the past 12 months.
What is Precision BioSciences’s market cap?
Currently, no data Available
When is Precision BioSciences’s upcoming earnings report date?
Precision BioSciences’s upcoming earnings report date is May 10, 2023 which is in 49 days.
How were Precision BioSciences’s earnings last quarter?
Precision BioSciences released its earnings results on Mar 09, 2023. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.202 by -$0.058.
Is Precision BioSciences overvalued?
According to Wall Street analysts Precision BioSciences’s price is currently Undervalued.
Does Precision BioSciences pay dividends?
Precision BioSciences does not currently pay dividends.
What is Precision BioSciences’s EPS estimate?
Precision BioSciences’s EPS estimate is -$0.24.
How many shares outstanding does Precision BioSciences have?
Precision BioSciences has 111,295,720 shares outstanding.
What happened to Precision BioSciences’s price movement after its last earnings report?
Precision BioSciences reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.202. Following the earnings report the stock price went down -11.304%.
Which hedge fund is a major shareholder of Precision BioSciences?
Among the largest hedge funds holding Precision BioSciences’s share is Caxton Associates LP. It holds Precision BioSciences’s shares valued at N/A.
---
Precision BioSciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.50 (1135.29% Upside)
$10.50 (1135.29% Upside)
Blogger Sentiment
Bullish
DTIL Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 166.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $17.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.13%
12-Months-Change
Fundamentals
Return on Equity
-147.28%
Trailing 12-Months
Asset Growth
12.61%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Precision BioSciences
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.
---
Merrimack Pharmaceuticals
―
Tenaya Therapeutics
―
Oric Pharmaceuticals
―
Anixa Biosciences
―
Alaunos Therapeutics
―
---